Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06791122 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

StatusCompleted
PhaseNot applicable
Started2025-01-23
View on ClinicalTrials.gov ↗
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They may continue using it for another 16 weeks. During the study, participants continue with their normal treatment for schizophrenia. Participants are in the study for about a year. During this time, they visit the study site every 2 months. During this study, doctors regularly check participants' schizophrenia symptoms and overall quality of life. Researchers may also compare the healthcare data of study participants with a similar group of people with schizophrenia who are not part of the study. The doctors also regularly check participants' health and take note of any unwanted effects.

Amendment history 1 change detected by DataLookout

2026-09-10
notable
Trial completed
Trial Details
NCT Number NCT06791122
Lead Sponsor Boehringer Ingelheim
Conditions Schizophrenia
Enrollment 262 participants
Start Date 2025-01-23
Primary Completion 2026-08-24 (estimated)
Study Completion 2026-08-24 (estimated)
Updated on ClinicalTrials.gov 2026-09-09